Johnson and Johnson 2009 Annual Report Download - page 7

     
CHAIRMAN’S LETTER 5
Our Consumer business
continues to distinguish itself with science-
based innovation, proprietary technologies
and recommendations by health care profes-
sionals.We are the premier consumer health
care business. Over a billion people around
the world count on our consumer products
for themselves and their families.
In , Consumer sales were $.
billion, growing  percent operationally
despite a soft economy.Operational sales
increased in the Skin Care, Women’s Health,
Oral Care and Wound Care franchises, with
growth in several product lines, including
® , ® , ® and
®. Innovation in iconic brands is a
cornerstone of our Consumer business.In
 we launched
®  
in the U.S. and
®  + Hair
Care, among others.
We also developed new ways of doing
business.Noteworthy developments include the opening of
the first
® store, in Mumbai, India; the expansion
of skin iD
™
, an online personalized acne solution sold directly to
consumers; and the selling of products on home shopping channels.
More than half of Consumer sales come from markets outside
the United States.Deep consumer insights into local markets and
relevant product introductions drive global expansion, particu-
larly in developing markets.Recent acquisitions continue to fuel
global growth, such as the thriving 
®
brand in China, Vania
Expansion SNC in Europe and
® , expanding
beyond its French heritage into new markets.
 The health care
landscape has changed at an unprecedented pace over the past
few years and will continue to evolve.
As the health care debate unfolds in the United States and other
markets, Johnson & Johnson supports reform that expands access
to care, improves the long-term sustainability of the U.S. health
care system and builds on the best aspects, including incentives for
medical progress.We believe that appropriate reforms can both
improve patient care and create growth opportunities for health
care companies.
Johnson & Johnson is well-positioned for a changing landscape.
We remain focused on adding value to the health care system,
developing programs that promote wellness and creating better
solutions for chronic care.We remain true to who we are,
motivated by the goal of providing meaningful innovations that
benefit society.
We care in ways that can change the
world.Beyond our medical breakthroughs, we are committed to
the people and causes that need our support.We work with hun-
dreds of partners worldwide to make life-changing and sustainable
dierences in health care.When natural disasters strike, such as
the earthquake in Haiti, we work with our partners to provide cash
as well as products from across our businesses.
Our philanthropic eorts globally focus on saving and improving
the lives of women and children, building health care capacity and
preventing diseases. At Johnson & Johnson
companies worldwide, our people make a
dierence in their local communities.
Putting others first reminds us that
Johnson & Johnson people can transcend
whatever challenges come our way.
As world citizens, we continually
make strides to enhance the sustainability
of our facilities and packaging.This year,
our annual report is more environmentally
friendly.We have adopted  percent
post-consumer recycled paper for the inside
pages, reduced the number of printed pages
and developed an online version, accessible
at www.investor.jnj.com/annualreport.
We invite you to join our sustainability
eorts by electing to receive next year’s
annual report and shareholder materials
electronically.A tear-o card at the end
of this report provides easy-to-follow
instructions.
 To you, our shareholders, I commit
that Johnson & Johnson will be a leader in health care.We have led
many firsts for the health care industry: the first antiseptic
bandages, the first soft disposable contact lenses and the first
coronary stent, among others.And we will continue this leadership
tradition well into the future.We are a company that is deeply
committed to what we do and to the people we serve.
Our enduring business model, the strength of our current
products, pipelines that have never been more robust, a strong
balance sheet and a growing global presence provide the critical
ingredients for sustained leadership.Most important, the people
of Johnson & Johnson carry on the Company’s legacy with an
inspiration of caring that passes from generation to generation
of employees.
For all these reasons, I remain confident that Johnson & Johnson
will lead in health care, drive important innovations for customers
and patients, and achieve long-term, superior rates of return for
you, our loyal shareholders.
William C. Weldon
Chairman, Board of Directors, and Chief Executive Ocer
March 
(Excludes purchased in-process research and development and other special items.
(Free cash ow is defined as operating cash ow less capital spending.
See Reconciliation of Non-GAAP Financial Measures, page .










.